Drug intelligence / Profile preview

DRCYO01

Development stage: Preclinical
Lead developer: DRC
Modality: Antibody-Based Therapeutics
Administration: Parenteral

Overview

DRCYO01 is an investigational antibody-based therapeutic being developed by DRC Medicine for the treatment of COVID-19 (SARS-CoV-2 infection). The drug is formulated as an injection and is currently in the basic research phase in Japan.

Other names: COVID-19 antibody drugCOVID19 antibody drugCOVID 19 antibody drugCOVID-19 antibody therapeuticCOVID19 antibody therapeuticCOVID 19 antibody therapeutic新型コロナウイルス感染症抗体医薬

Targets

TMPRSS2 (Transmembrane protease serine 2)

Beyond the preview

Go deeper on DRCYO01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DRCYO01.